{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:45:48Z","timestamp":1780407948149,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s12094-009-0343-9","type":"journal-article","created":{"date-parts":[[2009,5,5]],"date-time":"2009-05-05T11:43:48Z","timestamp":1241523828000},"page":"215-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pralatrexate, a new hope for aggressive T-cell lymphomas?"],"prefix":"10.1007","volume":"11","author":[{"given":"Antonio","family":"Rueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Quero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Medina-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,5,6]]},"reference":[{"key":"343_CR1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"N.L. Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361\u20131392","journal-title":"Blood"},{"key":"343_CR2","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon"},{"key":"343_CR3","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"The Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","unstructured":"The Non-Hodgkin\u2019s Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin\u2019s lymphoma. Blood 89:3909\u20133918","journal-title":"Blood"},{"key":"343_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"9","author":"J.R. Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD et al (1998) Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol 9:717\u2013720","journal-title":"Ann Oncol"},{"key":"343_CR5","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"International T-Cell Lymphoma Project","year":"2008","unstructured":"International T-Cell Lymphoma Project (2008) International peripheral T-cell and natural killer\/Tcell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124\u20134130","journal-title":"J Clin Oncol"},{"key":"343_CR6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","volume":"1","author":"B. Coiffier","year":"1990","unstructured":"Coiffier B, Brousse N, Peuchmaur M et al (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d\u2019Etude des Lymphomaes Aggressives). Ann Oncol 1:45\u201350","journal-title":"Ann Oncol"},{"key":"343_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11864-004-0020-8","volume":"5","author":"A.M. Evens","year":"2004","unstructured":"Evens AM, Gartenshaus RB (2004) Treatment of T-cell Non-Hodgkin\u2019s lymphoma. Curr Treat Opt Oncol 5:289\u2013303","journal-title":"Curr Treat Opt Oncol"},{"key":"343_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1023\/A:1008418727472","volume":"9","author":"A. Lopez-Guillermo","year":"1998","unstructured":"Lopez-Guillermo A, Cid J, Salar A et al (1998) Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 9:849\u2013855","journal-title":"Ann Oncol"},{"key":"343_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/annonc\/mdf033","volume":"13","author":"T. Rudiger","year":"2002","unstructured":"Rudiger T, Weisenburger DD, Anderson JR et al (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin\u2019s Lymphoma Classification Project. Ann Oncol 13:140\u2013149","journal-title":"Ann Oncol"},{"key":"343_CR10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1023\/A:1008439620513","volume":"9","author":"E. Campo","year":"1998","unstructured":"Campo E, Gaulard P, Zucca E et al (1998) Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas. Ann Oncol 9:835\u2013843","journal-title":"Ann Oncol"},{"key":"343_CR11","first-page":"508","volume":"11","author":"J.R. Molina","year":"2008","unstructured":"Molina JR (2008) Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs 11:508\u2013521","journal-title":"IDrugs"},{"key":"343_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2174\/187152008783497064","volume":"8","author":"A. Gangjee","year":"2008","unstructured":"Gangjee A, Jain HD, Kurup S (2008) Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II. Anticancer Agents Med Chem 8:205\u2013231","journal-title":"Anticancer Agents Med Chem"},{"key":"343_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10555-007-9049-z","volume":"26","author":"Y.G. Assaraf","year":"2007","unstructured":"Assaraf YG (2007) Molecular basis of antifolate resistance. Cancer Metastasis Rev 26:153\u2013181","journal-title":"Cancer Metastasis Rev"},{"key":"343_CR14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/bjc.1993.425","volume":"68","author":"H.S. Dhaliwal","year":"1993","unstructured":"Dhaliwal HS, Rohatiner AZ, Gregory W et al (1993) Combination chemotherapy for intermediate and high-grade non-Hodgkin\u2019s lymphoma. Br J Cancer 68:767\u2013774","journal-title":"Br J Cancer"},{"key":"343_CR15","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1053\/beha.2002.0231","volume":"15","author":"C. Patte","year":"2002","unstructured":"Patte C (2002) Treatment of mature B-ALL and high grade B-NHL in children. Best Pract Res Clin Hematol 15:695\u2013711","journal-title":"Best Pract Res Clin Hematol"},{"key":"343_CR16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/10428190701824569","volume":"49","author":"A.K. Fotoohi","year":"2008","unstructured":"Fotoohi AK, Albertioni F (2008) Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk Lymphoma 49:410\u2013426","journal-title":"Leuk Lymphoma"},{"key":"343_CR17","first-page":"18","volume":"12","author":"F.M. Sirotnak","year":"1984","unstructured":"Sirotnak FM, DeGraw JI, Moccio DM et al (1984) New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 12:18\u201325","journal-title":"Cancer Chemother Pharmacol"},{"issue":"[Suppl1]","key":"343_CR18","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1016\/0169-5002(95)00435-4","volume":"12","author":"R.J. Gralla","year":"1995","unstructured":"Gralla RJ (1995) Edatrexate studies in non-small cell lung cancer. Lung Cancer 12[Suppl 1]:S187\u2013191","journal-title":"Lung Cancer"},{"key":"343_CR19","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1021\/jm00067a020","volume":"36","author":"J.I. DeGraw","year":"1993","unstructured":"DeGraw JI, Colwell WT, Piper JR et al (1993) Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. J Med Chem 36:2228\u20132231","journal-title":"J Med Chem"},{"key":"343_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s002800050823","volume":"42","author":"F.M. Sirotnak","year":"1998","unstructured":"Sirotnak FM, DeGraw JI, Colwell WT et al (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 42:313\u2013318","journal-title":"Cancer Chemother Pharmacol"},{"key":"343_CR21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/1042819031000077124","volume":"44","author":"E.S. Wang","year":"2003","unstructured":"Wang ES, O\u2019Connor O, She Y et al (2003) Activity of a novel antifolate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 44:1027\u20131035","journal-title":"Leuk Lymphoma"},{"key":"343_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/01.cco.0000245309.74767.20","volume":"18","author":"O.A. O\u2019Connor","year":"2006","unstructured":"O\u2019Connor OA (2006) Pralatrexate: an emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol 18:591\u2013597","journal-title":"Curr Opin Oncol"},{"key":"343_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/1078-0432.CCR-05-0331","volume":"12","author":"L.E. Toner","year":"2006","unstructured":"Toner LE, Vrhovac R, Smith EA et al (2006) The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin\u2019s lymphoma. Clin Cancer Res 12:924\u2013932","journal-title":"Clin Cancer Res"},{"key":"343_CR24","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1172\/JCI109525","volume":"64","author":"E. Cadman","year":"1979","unstructured":"Cadman E, Eiferman F (1979) Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells. J Clin Invest 64:788\u2013797","journal-title":"J Clin Invest"},{"key":"343_CR25","first-page":"3493","volume":"6","author":"L.M. Krug","year":"2000","unstructured":"Krug LM, Ng KK, Kris MG et al (2000) Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res 6:3493\u20133498","journal-title":"Clin Cancer Res"},{"key":"343_CR26","first-page":"1370","volume":"110","author":"D.R. Mould","year":"2007","unstructured":"Mould DR, Sweeney K, Duffull S et al (2007) A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 110:1370","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"[Suppl12]","key":"343_CR27","first-page":"abstract 461","volume":"4","author":"O. O\u2019Connor","year":"2006","unstructured":"O\u2019Connor O, Hamlin P, Neylon E et al (2006) Early-phase experience with pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate with high affinity for the reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies. Eur J Cancer 4[Suppl 12]:abstract 461","journal-title":"Eur J Cancer"},{"key":"343_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1365-2141.2007.06658.x","volume":"139","author":"O\u2019Connor","year":"2007","unstructured":"O\u2019Connor, Hamlin PA, Portlock C et al (2007) Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 139:425\u2013428","journal-title":"Br J Haematol"},{"key":"343_CR29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jaad.2007.12.012","volume":"58","author":"J.J. Leitenberger","year":"2008","unstructured":"Leitenberger JJ, Berthelot CN, Polder KD et al (2008) CD4+ CD56+ hematodermic\/plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol 58:480\u2013484","journal-title":"J Am Acad Dermatol"},{"key":"343_CR30","doi-asserted-by":"crossref","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L et al (2008) PROPEL: a multi-center phase 2 open-label study of pralatrexate (PDX) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory peripheral T-cell lymphoma. Blood (ASH Annual Meeting Abstracts 2008) 112:Abstract 261","DOI":"10.1182\/blood.V112.11.261.261"},{"key":"343_CR31","doi-asserted-by":"crossref","unstructured":"Horwitz SM, Vose JM, Advani R et al (2008) A phase 1\/2A open-label study of pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies. Blood (ASH Annual Meeting Abstracts 2008) 112:Abstract 1570","DOI":"10.1182\/blood.V112.11.1570.1570"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-009-0343-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-009-0343-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-009-0343-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-009-0343-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:53:35Z","timestamp":1659095615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-009-0343-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["343"],"URL":"https:\/\/doi.org\/10.1007\/s12094-009-0343-9","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"5 October 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}